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Abstract 48 
Brain responses to transcranial magnetic stimulation (TMS) as measured with 49 
electroencephalography (EEG) have so far been assessed either by TMS-evoked EEG 50 
potentials (TEPs), mostly reflecting phase-locked neuronal activity, or time-frequency-51 
representations (TFRs), reflecting oscillatory power arising from a mixture of both 52 
evoked (i.e., phase-locked) and induced (i.e., non-phase-locked) responses. Single-53 
pulse TMS of the human primary motor cortex induces a specific pattern of oscillatory 54 
changes, characterized by an early (30-200 ms after TMS) synchronization in the α- and 55 
ß-bands over the stimulated sensorimotor cortex and adjacent lateral frontal cortex, 56 
followed by a late (200-400 ms) α- and ß-desynchronization over the stimulated and 57 
contralateral sensorimotor cortex. As GABAergic inhibition plays an important role in 58 
shaping oscillatory brain activity, we sought here to understand if GABAergic inhibition 59 
contributes to these TMS-induced oscillations. We tested single oral doses of 60 
alprazolam, diazepam, zolpidem (positive modulators of the GABAA receptor), and 61 
baclofen (specific GABAB receptor agonist). Diazepam and zolpidem enhanced, and 62 
alprazolam tended to enhance while baclofen decreased the early α-synchronization. 63 
Alprazolam and baclofen enhanced the early ß-synchronization. Baclofen enhanced the 64 
late α-desynchronization, and alprazolam, diazepam and baclofen enhanced the late ß-65 
desynchronization. The observed GABAergic drug effects on TMS-induced α- and 66 
β-band oscillations were not explained by drug-induced changes on corticospinal 67 
excitability, muscle response size, or resting-state EEG power. Our results provide first 68 
insights into the pharmacological profile of TMS-induced oscillatory responses of motor 69 
cortex.  70 
  71 
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1. Introduction 72 
The combination of transcranial magnetic stimulation and electroencephalography 73 
(TMS-EEG) is a powerful approach to assess aspects of cortical excitation and 74 
inhibition (Chellappa et al., 2016; Chung et al., 2015; Ilmoniemi and Kicic, 2010; 75 
Ziemann, 2011). TMS-evoked EEG potentials (TEPs) represent the averaged time-76 
locked brain response to single-pulse TMS in the time domain, which likely involves 77 
both excitatory and inhibitory neuronal processes (Rogasch and Fitzgerald, 2013). So 78 
far, the most direct evidence for the role of inhibition in the generation of TEPs comes 79 
from pharmacological studies that assessed the impact of central nervous system 80 
(CNS) active drugs that modulate GABAergic neurotransmission (Darmani et al., 2016; 81 
Premoli et al., 2014a; Premoli et al., 2014b). However, pharmacological TMS studies 82 
have so far only considered the impact of TMS in the time domain, while also the 83 
frequency domain provides relevant and complementary information about the brain 84 
response to TMS (Herring et al., 2015; Rosanova et al., 2009).  85 
Calculating the time-frequency representation (TFR) of the oscillatory EEG 86 
response to TMS allows to simultaneously assess power levels in a variety of 87 
frequencies in a time resolved manner. Importantly, oscillatory responses to TMS can 88 
either be evoked (i.e. phase-locked) or induced (i.e. non-phase-locked) by the 89 
stimulation, and each single trial can reflect a combination of both (i.e., mixed response) 90 
(Herrmann et al., 2014; Pellicciari et al., 2017). Evoked responses may either result 91 
from an additive neuronal response elicited by the stimulation or a phase-reset of 92 
ongoing (spontaneous) oscillations (David et al., 2006). Evoked oscillations can be 93 
calculated on the average of single-trials (i.e., TEP), as most of the non-phase-locked 94 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Premoli and others 5
activity is cancelled out by averaging in the time domain. In contrast, induced responses 95 
result from the stimulus-related modulation of the amplitude but not the phase of an 96 
ongoing oscillation, and they are generally estimated by means of event-related 97 
synchronization and desynchronization (Pfurtscheller and Aranibar, 1977). Induced 98 
oscillations are detected when TFRs are estimated on the single-trial level and 99 
averaged subsequently, e.g. when calculating the so-called event-related spectral 100 
perturbation (ERSP) index (Makeig, 1993). However, ERSP provides a mixed response 101 
as this procedure is equally sensitive for induced and evoked oscillations and cannot 102 
discriminate the two oscillatory response types (Herrmann et al., 2014; Pellicciari et al., 103 
2017). Previous TMS-EEG studies have either focused on TMS-evoked responses 104 
(Bonato et al., 2006; Farzan et al., 2013; Garcia et al., 2011; Herring et al., 2015; Paus 105 
et al., 2001) or on mixed responses (Ferrarelli et al., 2008; Ferrarelli et al., 2012; 106 
Johnson et al., 2012; Rosanova et al., 2009). For TMS of the hand area of the primary 107 
motor cortex (M1HAND), mixed oscillatory responses in the α- and β-band have been 108 
reported to transiently emerge in proximity of the stimulated site (Brignani et al., 2008; 109 
Fuggetta et al., 2005; Paus et al., 2001; Veniero et al., 2011). However, a systematic 110 
study of TMS-induced oscillations and their underlying neuronal mechanisms is still 111 
lacking.  112 
To further explore TMS-related oscillations as novel indicators of cortical 113 
processes we sought to disentangle TMS-induced from the contribution of TMS-evoked 114 
oscillations and analyze their GABAergic pharmacological profile. For this purpose, we 115 
reanalyzed the data from two previously published experiments (Premoli et al., 2014a), 116 
in which the respective roles of different α-subunit-containing GABAARs (Experiment 1) 117 
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and GABABRs (Experiment 2) was investigated, as they underlie different physiological 118 
(Mohler et al., 2002) and pathological (Cossette et al., 2002) functions. In Experiment 1, 119 
we investigated the effects of alprazolam, a classical benzodiazepine and positive 120 
modulator of α1-, α2-, α3- and α5-containing GABA type A receptors (GABAAR), and 121 
zolpidem, a short-acting non-benzodiazepine hypnotic drug, which mainly binds to the 122 
α1-containing GABAAR. In Experiment 2, we tested the effects of diazepam, another 123 
classical benzodiazepine binding to α1-, α2-, α3- and α5-containing GABAARs, and 124 
baclofen, a specific GABAB receptor (GABABR) agonist. 125 
Understanding the neuropharmacological basis of TMS-induced oscillations is of 126 
fundamental importance as this knowledge may lead to new markers of excitatory and 127 
inhibitory processes in the human brain, which could be used for detecting abnormal 128 
excitability in brain disorders. 129 
 130 
2. Methods and Materials 131 
2.1 Subjects 132 
Twenty-two (Experiment 1, mean age: 25.0 ± 2.5 years, range: 21–32 years) and 19 133 
male healthy subjects (Experiment 2, mean age: 26.4 ± 3.5 years; range: 22–32 years) 134 
gave written informed consent before enrolment in this study. Here, the data presented 135 
are from 16 and 15 subjects, respectively for Experiment 1 and 2, as several subjects 136 
had to be excluded due to data quality issues (see below). The TMS-evoked EEG 137 
potential (TEP) analyses of this sample have already been published (Premoli et al., 138 
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2014a) and is outside the scope of this paper. Female participants were not recruited 139 
because of menstrual cycle-related effects on cortical excitability, which can be a 140 
potential confound in TMS studies (Smith et al., 1999). Subjects were tested for right-141 
handedness following the Edinburgh Handedness Inventory (laterality score ≥75%) 142 
(Oldfield, 1971). All participants were screened for contraindications to TMS during a 143 
physical and neurological examination (Rossi et al., 2011). Exclusion criteria 144 
encompassed the presence of a history of neurological or psychiatric disease, use of 145 
CNS active drugs, abuse of any drugs (including nicotine and alcohol) as well as 146 
contraindications to the study medications. Experiments were approved by the Federal 147 
Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und 148 
Medizinprodukte), and by the local Ethics Committees of the Medical Faculty of Goethe-149 
University Frankfurt (Experiment 1) and the Medical Faculty of Eberhard-Karls-150 
University Tübingen (Experiment 2). 151 
2.2 Experimental design 152 
We performed two double-blind, randomized, crossover design studies to investigate 153 
the impact of GABAAR (Experiment 1) and GABABR (Experiment 2) mediated inhibitory 154 
neurotransmission on TMS-induced oscillations. In Experiment 1 we tested the acute 155 
effects of a single oral dose of alprazolam (1 mg, Alprazolam ratiopharm, ratiopharm), 156 
zolpidem (10 mg, Zolpidem-ratiopharm, ratiopharm), or placebo (P-Tabletten 157 
Lichtenstein). In Experiment 2 we tested a single oral dose of baclofen (50 mg Lioresal, 158 
Novartis Pharma), diazepam (20 mg Diazepam-ratiopharm, ratiopharm), or placebo (P-159 
Tabletten Lichtenstein).  160 
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In both studies, subjects participated in three experimental sessions, randomized 161 
in order and separated by one week to avoid drug carryover effects. Both resting state 162 
EEG (3 min with eyes open) and TMS-EEG measurements were performed 163 
immediately before and 90 min after drug intake (Figure 1). In Experiment 1 only 13 164 
subjects underwent resting state EEG measurements. Drug dosages and post-drug 165 
measurement time were chosen according to the pharmacokinetic properties of the 166 
study drugs (Greenblatt and Wright, 1993; Salva and Costa, 1995; Shader et al., 1984), 167 
as well as to our previous TMS-electromyography (TMS-EMG) studies that have 168 
demonstrated significant modulation of motor cortical excitability (Ilic et al., 2002; 169 
McDonnell et al., 2006; Müller-Dahlhaus et al., 2008). 170 
 171 
Figure 1. Timeline of experiments: Resting Motor Threshold (RMT), 3 min of resting state EEG (RS-172 
EEG) and TMS-EEG measurements were performed before (pre-drug) and 90 minutes after (post-drug) 173 
the intake of alprazolam (ALP), zolpidem (ZOL) or placebo (PBO) in Experiment 1, and baclofen (BAC), 174 
diazepam (DIA) and PBO in Experiment 2. RMT was not registered post-drug in Experiment 1. 175 
2.3 TMS 176 
A figure-of-eight coil (external diameter of each wing, 90 mm) connected to a Magstim 177 
2002 magnetic stimulator (The Magstim Company Ltd., Whitland, UK) with a 178 
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monophasic current flow was used to deliver single-pulse TMS to the left M1HAND. We 179 
targeted the representation of the right abductor pollicis brevis muscle (APB), which was 180 
determined as the site where TMS at a slightly suprathreshold intensity consistently 181 
produced the largest motor evoked potentials (MEPs) (Rossini et al., 2015). MEP 182 
recordings were obtained from surface EMG, using Ag-AgCl cup electrodes in a belly–183 
tendon montage. The EMG raw signal was amplified and bandpass filtered (20 Hz to 2 184 
kHz; D360 amplifier, Digitimer) and digitized at an A/D rate of 10 kHz (CED Micro 1401; 185 
Cambridge Electronic Design). The coil was placed tangential to the scalp with the 186 
handle pointing backwards and 45° away from the mid line, inducing a posterolateral to 187 
anteromedial current in the brain. This is the optimal orientation to transsynaptically 188 
activate the corticospinal system via horizontal corticocortical connections (Di Lazzaro 189 
et al., 2008). Resting motor threshold (RMT) was determined to nearest 1% of 190 
maximum stimulator output, following the relative frequency method (Rossini et al., 191 
2015), that is the minimum intensity necessary to elicit an MEP of ≥ 50 µV in peak-to-192 
peak amplitude in at least 5 of 10 subsequent trials. A number of 150 TMS pulses 193 
(Experiment 1) and 125 TMS pulses (Experiment 2) each were applied over the left M1 194 
APB hotspot at an intensity of 100% RMT. In Experiment 1, RMT was tested pre-drug 195 
only, and stimulation intensity was kept constant throughout all measurements, whereas 196 
in Experiment 2, RMT was tested pre- and post-drug to assess possible drug-induced 197 
changes in RMT (Figure 1) and re-adjust stimulation intensity to keep it constant at 198 
relative to 100% RMT. Per definition, this stimulation intensity elicited MEPs ≥ 50 µV in 199 
approximately half of the trials. Only for Experiment 2, EMG was co-registered also 200 
during the TMS-EEG measurements. The position of the APB hotspot was marked with 201 
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a felt tip pen on the EEG cap to ensure constant coil placement throughout an 202 
experimental session. Further, coil position and orientation relative to the marked 203 
position were carefully monitored by the experimenter throughout stimulation and 204 
corrected if necessary (i.e., if the participant moved). Importantly, any lack of precision 205 
(relative to the use of a neuronavigation system) would have resulted only in increased 206 
unsystematic error variance (and potentially false negatives), but the double-blind 207 
design ensured that no systematic bias (and thus no false positives) could be 208 
introduced. 209 
2.4 High-density EEG recordings during TMS 210 
A 64-channel electrode cap (BrainCap-Fast’n Easy 64Ch, Brain Products) connected to 211 
TMS-compatible EEG amplifiers (BrainAmp DC, BrainProducts) was used to record 212 
brain oscillations, hardware-filtered between 0.016 and 1000 Hz and digitized with a 5 213 
kHz sampling rate. Vertical electrooculogram was recorded with 2 additional electrodes 214 
to measure eye movements and blinks. Impedances of all electrodes were kept < 5 kΩ. 215 
During TMS-EEG recordings, subjects were seated on a comfortable reclining chair and 216 
asked to stay awake with eyes open. Masking white noise was played through 217 
earphones to avoid contamination of the EEG signal by auditory potentials evoked by 218 
the click of the discharging TMS coil (Casarotto et al., 2010; Massimini et al., 2005). The 219 
noise intensity was adjusted individually in each experimental session, until the 220 
participant reported not being able anymore to hear the TMS-click. While residual input 221 
via bone conduction cannot be completely excluded, based on their topography our 222 
results cannot be explained by auditory evoked potentials. During EEG co-registration, 223 
we applied 2 blocks of 125 TMS pulses each pre- and post-drug over the left M1HAND 224 
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APB hotspot. The inter-stimulus interval between TMS pulses was on average 5 s with 225 
a random inter-trial interval variation of 25% to reduce trial anticipation. 226 
2.5 TMS-EEG data analysis 227 
This study is based on data from our two previously published experiments with an 228 
original dataset of 22 (Experiment 1) and 19 (Experiment 2) subjects (Premoli et al., 229 
2014a). In this work, data from 2 subjects in Experiment 1 and 4 subjects in Experiment 230 
2 had to be excluded from final analysis because of excessive artifact contamination of 231 
the EEG traces. In addition, in Experiment 1, data from other 5 subjects had to be 232 
excluded as they were particularly affected by Magstim 2002 capacitors recharge 233 
artifact. Note that analyses, including artifact removal, trial rejection, and subject 234 
exclusion were performed completely blind towards experimental condition. 235 
TMS-EEG data were analyzed by using MATLAB® (Mathworks Ltd, USA, R2012b) (The 236 
Mathworks Inc.), EEGLAB (Delorme and Makeig, 2004) and FieldTrip toolboxes 237 
(Oostenveld et al., 2011). After visual inspection, trials affected by prominent artifacts 238 
(i.e. eye and muscle movement) were removed, and bad channels were deleted and 239 
spatially interpolated. On average, 80 trials were retained for analysis per data set. A 240 
linear interpolation was applied between -2 and 6 ms relative to the TMS pulse to 241 
remove the initial TMS artifact caused by the step-response of the amplifier. In 242 
Experiment 2 an additional linear interpolation (between -102 and -94 ms) was used to 243 
remove a TMS-recharge artifact at -100ms. This technical artifact was related to the 244 
effectively omitted conditioning pulse (i.e. with intensity of 0 % MSO) from the paired-245 
pulse TMS trials that was part of the same protocol (Premoli et al., 2014b). Data were 246 
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then linearly detrended, band-pass (1-45 Hz) and band-stop filtered (49-51 Hz), 247 
segmented (-600 to 600 ms), down-sampled to 625 Hz, and referenced to the common 248 
average of all electrodes. Independent Component analysis (ICA) was then applied to 249 
remove remaining TMS-related artifacts (i.e., the cranial muscle response, the 250 
recharging of capacitors, and related exponential decay artifacts (Herring et al., 2015; 251 
Korhonen et al., 2011; Rogasch et al., 2016)), as well as further muscle and ocular 252 
activity. Artifact components were removed if their spatio-temporal profile indicated the 253 
activation of temporal muscles by a characteristic sinusoidal waveform peaking around 254 
5 and 15 ms post-TMS (with opposite sign) over frontotemporal sites close to the 255 
temporal muscle (Mutanen et al., 2013). Due to excessive artifact contamination, data 256 
from six and four subjects had to be excluded from Experiment 1 and 2, resulting in 16 257 
and 15 subjects, respectively. Note that analyses, including artifact removal, trial 258 
rejection, and subject exclusion were performed completely blind towards experimental 259 
condition.  260 
Time-frequency representations (TFRs) of TMS-related oscillatory power 261 
changes were calculated, separately for each pre- and post-drug condition, by means of 262 
a Hanning taper windowed FFT with frequency-dependent window length (width: 3.5 263 
cycles per time window, time steps: 10 ms, frequency steps: 1 Hz from 8 to 30 Hz) 264 
(Delorme and Makeig, 2004) (Figure 2B). We divided neuronal response components 265 
into those evoked (i.e. phase-locked) vs. induced (i.e. non-phase-locked) by TMS 266 
(Figure 2A, (Cohen and Donner, 2013; Donner and Siegel, 2011; Herrmann et al., 267 
2014; Pellicciari et al., 2017)). The TFR of the induced response was then isolated by 268 
subtracting the individual time-domain average from each trial before calculating the 269 
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TFRs of the single trials (as done in Cohen and Donner, 2013, but note that we used a 270 
sliding window FFT instead of complex Morlet wavelets to calculate the TFRs; Figure 271 
2D) instead of subtracting the average TFR of the evoked response form the average 272 
TFR of the total response (as suggested in Herrmann et al., 2014; Pellicciari et al., 273 
2017). The former approach was preferred since we performed single-trial normalization 274 
by z-transforming the TFR of each trial for each frequency, which the latter approach 275 
would not allow. The z-transformation was based on the respective mean and standard 276 
deviation derived from the full trial length. This was followed by an absolute baseline 277 
correction for each trial by subtracting the average of the -400 to -200 ms period (this 278 
artifact-free baseline window was chosen because the presence of a technical artifact at 279 
-100ms did not allow a later window; see above) for each frequency to ensure z-values 280 
represent a change from pre-TMS baseline. Subsequently, TFRs were averaged across 281 
trials per experimental condition. This procedure resulted in an event related spectral 282 
perturbation (ERSP) measure that is robustly normalized based on the single trial level 283 
(Grandchamp and Delorme, 2011), however, with the contribution of the TMS-evoked 284 
response removed at the single-trial level. Finally, TFRs were cropped to the time of 285 
interest (-400 to 400 ms), removing time-frequency bins at the trial edges for which no 286 
values could be computed. Values were averaged across frequency bins to calculate 287 
the power within the α (8-12 Hz) and β (13-30 Hz) frequency bands, which represent the 288 
dominating oscillations of the sensorimotor cortex (Engel and Fries, 2010; Jensen et al., 289 
2005; Neuper et al., 2005). While this approach for disentangling TMS-induced from 290 
TMS-evoked oscillations is naturally imperfect (slight trial-by-trial variations in the 291 
latency and amplitude of the TEP waveform are not captured and result in small 292 
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subtraction errors, which may be misinterpreted as induced power) it is to the best of 293 
our knowledge currently the best method available. In this particular study, the specific 294 
pattern of early synchronization and late desynchronization is not observed in 295 
TMS-evoked responses and is thus highly unlikely to reflect mere residuals of evoked 296 
activity (Figure 2).  297 
 298 
 299 
 300 
Figure 2. Disentangling TMS-induced and TMS-evoked oscillations. (A) Illustration of the method used 301 
to disentangle induced from evoked oscillatory responses for a single TMS-EEG session of a 302 
representative subject. The average time-locked evoked response is subtracted from every single trial 303 
before calculating the TFR, thus capturing the non-phase-locked (i.e. induced) oscillatory responses only 304 
(see Methods for details). (B) Time-frequency representation (TFR) of the mixed TMS-related power 305 
change, shown for conceptual reasons only (obtained by calculating TFRs on the single-trial level without 306 
previous removal of the evoked response). (C) TMS-evoked oscillations, shown for conceptual reasons 307 
only (obtained by calculating the TFR of the individual average TEP, i.e. after averaging the time-locked 308 
signal across trials in the time domain). (D) TMS-induced oscillations (obtained by calculating the TFR at 309 
single-trial level after removal of the evoked component, see Methods section for details). Results are 310 
shown for electrode C3 (approximately overlying the stimulated left M1HAND) and correspond to the 311 
grand-average across subjects and across the three pre-drug conditions of Experiment 1. The black box 312 
in proximity of 0 highlights the residual of the TMS artifacts and corresponds to the time window which 313 
was not included in the analysis. Note that the common, symmetrical color scaling for all subpanels 314 
facilitates visibility of the late desynchronization but causes a saturation for synchronization values 315 
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leading to an apparent fusion (particularly for mixed responses in B) of the broadband power increase 316 
during the residual TMS-related artifact (approx. -30 to 30 ms) and the subsequent oscillatory 317 
synchronization in alpha and beta bands (approx. 30- 200 ms; TOI1). Also note the clear demarcation 318 
line with z-values close to zero between these two areas for the TMS-induced oscillations (D) under 319 
investigation. 320 
 321 
2.6 TMS-EMG data analysis 322 
For Experiment 2, EMG had been co-registered during TMS-EEG measurements and 323 
MEP peak-to-peak amplitudes were evaluated for each trial. MEP amplitudes were 324 
calculated as difference between the maximum and minimum of the EMG signal as 325 
extracted from an individualized search window to account for differences in MEP 326 
latency. The individual search window was defined based on the average TMS-locked 327 
EMG waveform (but always within the limits of 0.015 to 0.045 s post-TMS). MEP data 328 
was only available for both pre- and post-drug measurements for 12 subjects (baclofen) 329 
and 13 subjects (diazepam and placebo). Average MEP amplitudes were compared 330 
between pre- and post-drug measurements using paired-sample t-tests. Single-trial 331 
MEP amplitudes were further used to split the above described analysis of TMS-332 
induced oscillatory power into subthreshold (< 0.05 mV) and suprathreshold (≥ 0.05 mV) 333 
trials.  334 
2.7 Resting state EEG data analysis 335 
GABAergic drugs, such as diazepam (Jensen et al., 2005; Saletu et al., 1987), 336 
alprazolam (Kaplan et al., 1998), and zolpidem (de Haas et al., 2010) are known to also 337 
affect spontaneous oscillations at rest. However, to the best of our knowledge the effect 338 
of baclofen has not yet been tested with quantitative EEG in awake human subjects. To 339 
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investigate the relationship between drug-induced changes of TMS-induced and 340 
spontaneous oscillations, 3 min segments of eyes open resting state EEG data were 341 
analyzed as well. Data were initially divided into non-overlapping 2 s time-windows. A 342 
Morlet-wavelet convolution (width of 5 cycles, in time steps of 10 ms and frequency 343 
steps of 1 Hz from 8 to 45 Hz) was used to analyze the power spectra of the resting 344 
state EEG signal before and after drug intake in the α (8-12 Hz) and β (13-30 Hz) 345 
frequency bands. We performed a correlational analysis to explore a possible relation of 346 
drug-induced changes in TMS-induced and spontaneous resting state EEG oscillations. 347 
To pursue this, we extracted the power values for each spectral band, for each subject, 348 
before and after drug administration in those channels that showed a drug-induced 349 
change in both TMS-induced and spontaneous power (see Results). Those channels 350 
were selected to test whether changes in spontaneous oscillations may affect changes 351 
in TMS-induced oscillations. Spearman correlation analyses were run between the 352 
TMS-induced power change (power post-drug minus power pre-drug) and the resting 353 
state EEG power modulation (power post-drug minus power pre-drug) in the different 354 
drug conditions. 355 
2.8 Statistics  356 
Significant differences in TMS-induced α-band (8-12 Hz) and β-band (13-30 Hz) power 357 
changes from baseline (pre-TMS) were assessed using non-parametric permutation 358 
tests based on one-sample t-statistics (Maris and Oostenveld, 2007) comparing the 359 
z-normalized TFRs against zero, as the pre-TMS baseline is zero on average by 360 
definition (due to the above described baseline subtraction after full trial 361 
z-normalization). The analysis was performed in two fixed time windows of interest 362 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Premoli and others 17
(TOIs), an early (30-200 ms; TOI1) and a late (200-400 ms; TOI2) window. TOIs were 363 
chosen on the basis of the grand average of the pooled pre-drug measurements to track 364 
power changes over time, and TOIs were kept identical for each statistical comparison 365 
(Figure 2D) (Grent-'t-Jong et al., 2016). Note that TOI1 is close to spurious power 366 
increases due to residual TMS-artifacts (approx. -30 to 30  ms), but that (i) a clear 367 
demarcation line can be seen between the two areas for the TMS-induced oscillations 368 
under investigation (cf. Figure 2D, Figure 3, and Figure 5), and that (ii) no systematic 369 
confounds can arise from any residual TMS-related artifacts (as they are independent of 370 
the pharmacological interventions).  371 
To analyze drug modulation on TMS-induced α- and β-bands oscillatory power, multiple 372 
non-parametric permutation tests based on dependent-sample t-statistics (Maris and 373 
Oostenveld, 2007) were run between the different conditions (post- vs. pre-drug), 374 
separately for each drug condition and TOIs. To correct for multiple comparisons due to 375 
the large number of electrodes and time points within TOIs, we additionally conducted 376 
cluster based permutation tests (Maris and Oostenveld, 2007) as implemented in 377 
FieldTrip (http://fieldtrip.fcdonders.nl). Thus, a non-parametric permutation test (Monte-378 
Carlo method based on paired t-statistics) comparing the post-drug versus pre-drug 379 
condition was performed for each electrode at each time bin within the two different 380 
TOIs while averaging over the frequency bins of the spectral band of interest. Then, 381 
t-values exceeding an a priori threshold of p < 0.05 were clustered based on adjacent 382 
time bins and neighboring electrodes. Cluster-level statistics were calculated by taking 383 
the sum of the t-values within each cluster. The statistical comparisons were performed 384 
with respect to the maximum values of summed t-values. By means of a permutation 385 
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test (i.e., randomizing data across post-drug and pre-drug conditions and rerunning the 386 
statistical test 1500 times), we obtained a reference distribution of the maximum of 387 
summed cluster t-values to evaluate the statistic of the actual data. Clusters in the 388 
original dataset were considered to be significant at p < 0.05 if < 5% of the permutations 389 
used to construct the reference distribution yielded a maximum cluster-level statistic 390 
larger than the cluster-level value observed in the original data. 391 
Finally, the cluster-based permutation approach was also used to evaluate drug-392 
induced power changes in spontaneous α- and β-band oscillations in the resting state 393 
EEG (i.e., in the absence of TMS). Multiple dependent t-tests were run between the 394 
different conditions (post- vs. pre-drug), separately for each drug condition. 395 
3. Results 396 
3.1 Characterization of TMS-induced oscillations before drug intake 397 
Compared to pre-TMS baseline, time-frequency representation of TMS-induced 398 
oscillations revealed a significant power increase (i.e. synchronization) in the β-band 399 
(13-30 Hz) in TOI1 (p < 0.001, from 30 to 200 ms in both Experiment 1 and 2) and a 400 
significant β-band power decrease (i.e. desynchronization) encompassing bilateral 401 
sensorimotor cortices in TOI2 (p < 0.05, from 200 to 400 ms in both Experiments; 402 
Figure 3A-B). For the α-band (8-12 Hz), only the early synchronization in TOI1 was 403 
significant (p = 0.001 for both Experiments) but not the late desynchronization (p > 0.05; 404 
Figure 3A-B); but there were significant increases in α-band power in TOI2 for frontal 405 
and posterior clusters (p = 0.003 and p = 0.03, respectively). The topographic 406 
distribution of induced power changes for α- and β-bands, shown in Figure 3C, 407 
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suggests maximal effects over the stimulated left M1 in both TOIs, with an additional 408 
homologue cluster in the contralateral right hemisphere (usually smaller and located 409 
slightly more anterior) for the α- and β-power desynchronization in TOI2. Topographical 410 
information is only based on sensor-level data, and should thus be interpreted with care. 411 
 412 
 413 
Figure 3. Characterization of TMS-induced oscillations at pre-drug baseline. Grand average of the 414 
time-frequency representation (TFR) of TMS-induced oscillations (averaged across subjects and the three 415 
pre-drug measurements) recorded at the C3 electrode as the best representation of the stimulated left 416 
M1HAND in Experiment 1 (A) and Experiment 2 (B). TMS induced β-band (13-30 Hz) synchronization in 417 
TOI1 (30-200 ms) and ß-desynchronization in TOI2 (200-400 ms). Topographical distribution of the 418 
average power in the respective frequency band at sensor level is shown in (C) for both TOI1 (top row) 419 
and TOI2 (bottom row) in each of the analyzed frequency bands. High-frequency noise at -100ms shown 420 
in panel B represents residual TMS-recharge artifact after interpolation due to the paired-pulse protocol 421 
(note that no actual TMS pulse was applied at -100 ms in the analyzed trials, see Methods section). The 422 
black boxes in proximity of 0 sec in A-B highlight the residual of the TMS artifacts and correspond to the 423 
time window which was not included in the analysis. 424 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Premoli and others 20
3.2 Effects of GABAAR mediated inhibition on TMS-induced oscillations: Experiment 1 425 
Cluster-based permutation analyses revealed no differences in oscillatory power 426 
between pre-drug conditions (all p > 0.05). Alprazolam resulted in a trend towards 427 
increased α-band synchronization in TOI1 (p = 0.08), but significantly reduced ß-band 428 
synchronization in TOI1 (p = 0.02), and increased ß-band desynchronization in TOI2 429 
(p = 0.04; Figure 4A). Both effects appeared over left fronto-central electrodes. 430 
Zolpidem increased the TMS-induced α-band synchronization in TOI1 over channels 431 
close to the stimulated left M1HAND (p = 0.005; Figure 4B). Placebo showed no effect in 432 
any of the frequency bands or TOIs (all p > 0.05). The comparison of post-drug 433 
conditions to placebo confirmed that zolpidem increased α-band synchronization in 434 
TOI1 (p = 0.01), and that alprazolam decreased ß-band synchronization in TOI1 (p = 435 
0.002) and increased ß-band desynchronization in TOI2 (p = 0.03).  436 
3.3 Effects of GABAAR and GABABR mediated inhibition on TMS-induced oscillations: 437 
Experiment 2 438 
Cluster-based permutation analyses showed no differences in oscillatory power 439 
between pre-drug conditions (p > 0.05). Baclofen significantly reduced TMS-induced 440 
oscillations in the ß-band in TOI1 in a widespread area including the stimulated left 441 
sensorimotor cortex as well as left frontal and right parieto-occipital regions (p = 0.003). 442 
This effect was followed during TOI2 by an increase of α- and β-band 443 
desynchronization with a roughly comparable topography (both p = 0.001; Figure 4C). 444 
Diazepam increased α-band synchronization in TOI1 at electrodes close the stimulated 445 
sensorimotor cortex (p = 0.04), and increased β-band desynchronization in TOI2 mainly 446 
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in right frontal and centro-parietal sites (p = 0.01; Figures 4D). No significant 447 
modulation of TMS-induced oscillations was observed in the placebo condition in either 448 
TOI (p > 0.05). The comparison of post-drug conditions to placebo confirmed that 449 
baclofen decreased ß-band synchronization in TOI1 (p = 0.003), and that diazepam 450 
increased ß-band desynchronization in TOI2 (p = 0.04). 451 
452 
Figure 4. Topographies of significant drug-induced changes in TMS-induced oscillatory power. 453 
Topographies of drug-induced changes in TMS-induced oscillatory power are shown for alprazolam (A) 454 
and zolpidem (B) from Experiment 1 and for baclofen (C) and diazepam (D) from Experiment 2, 455 
separately for α- (8-12 Hz) and β-band (13-30 Hz) power and for TOI1 (30-200 ms) and TOI2 (200-400 456 
ms). (A) Alprazolam decreased β-band synchronization in TOI1 and further increased β-band 457 
desynchronization in TOI2, both in left frontal regions. (B) Zolpidem only increased α-band 458 
synchronization in TOI1 in left centro-parietal and right frontal regions. (C) Baclofen decreased β-band 459 
synchronization in TOI1 and increased both α- and β-band desynchronization in TOI2. (D) Diazepam 460 
increased TMS-induced α-band synchronization in TOI1 in left central regions and increased β-band 461 
desynchronization in right frontal and medial centro-parietal regions. Significant electrodes (p < 0.05, 462 
cluster corrected) are denoted with crosses in the t-statistic maps. 463 
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3.4 Effects of drugs on MEPs  464 
We aimed to ensure that the observed drug changes in TMS-induced oscillations 465 
cannot be explained by concurrent pharmacological changes in either corticospinal 466 
excitability or somatosensory re-afferent feedback due to the TMS-evoked muscle 467 
twitch, a potential confounding factor (Fecchio et al., 2017; Petrichella et al., 2017). 468 
Therefore, we analyzed the average amplitude of MEPs and the proportion of trials with 469 
suprathreshold MEPs obtained during the TMS-EEG recordings of Experiment 2 (no 470 
EMG data was co-registered during TEP measurements for Experiment 1). Since TMS 471 
intensity for TEP recordings was set to 100% RMT, roughly 50% each of trials with 472 
subthreshold and suprathreshold MEP were obtained (Table 1). RMT increased after 473 
the intake of baclofen (p = 0.028) and diazepam (p = 0.004), but not after placebo (p > 474 
0.2). After post-drug re-adjustment of stimulus intensity to 100% RMT, there were no 475 
post- vs. pre-drug differences for average MEP amplitude or the proportion of 476 
suprathreshold trials in any of the drug conditions (Table 1). 477 
3.5 Contribution of MEP-related afferent feedback to TMS-induced oscillatory power 478 
Since somatosensory stimulation alone can induce α- and β-desynchronization (Neuper 479 
et al., 2005), and TMS-evoked muscle twitches in the contralateral hand muscles are 480 
inevitably associated with somatosensory afferent feedback from muscle spindles 481 
reentering the sensorimotor cortex, we tested for Experiment 2 (for which MEP data 482 
was available) whether the observed TMS-induced α- and β-band desynchronization 483 
can be explained by the presence or absence of suprathreshold MEPs > 0.05 mV 484 
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(Rossini et al., 2015). According to the stimulation intensity of 100% RMT, per definition 485 
roughly half of the trials were supra- and subthreshold trials, respectively (Table 1). 486 
  487 
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Table 1: RMT (% maximum stimulator output, %MSO), MEP amplitudes (mV) and proportion of 488 
suprathreshold MEPs (%) for pre- and post-drug conditions of Experiment 2. 489 
  pre-drug post-drug t-test (post-pre) 
 
RMT 
%MSO 
Amp 
(mV) 
% 
supra 
RMT 
%MSO 
Amp 
(mV) 
% 
supra 
RMT Amp  % supra 
Baclofen 
44.07  
±  
4.37 
0.15  
±  
0.1   
50.43  
± 
18.16 
44.87 
±  
4.79 
0.20 
±  
0.12 
58.66 
± 
16.28 
t15 = 2.45 
p = 0.028 
t11 = 1.31 
p = 0.22 
t11 = 1.10 
p = 0.29 
Diazepam 
44.60  
±  
5.04 
0.16  
±  
0.11 
53.19  
±  
23.09 
46.80  
±  
5.71 
0.17 
±  
0.11 
51.58 
±  
20.64 
t15 = 3.51 
p = 0.004 
t12 = 0.06 
p = 0.95 
t12 = -0.15 
p = 0.88 
Placebo 
44.80  
±  
4.75 
0.18  
±  
0.10 
56.62  
±  
20.59 
45.20  
±  
4.57 
0.23 
±  
0.16 
56.65 
±  
26.06 
t15 = 1.19 
p = 0.25 
t12 = 1.91  
p = 0.08 
t12 = 0.18 
p = 0.86 
Mean ± SD as well as t-statistic and p-value are provided for post-pre comparisons per drug condition. 490 
Different degrees of freedom result from varying number of available datasets (N = 15 for RMT 491 
measurements; N = 12 (baclofen) and N = 13 (diazepam and placebo) for co-registered EMG (MEP and 492 
% supra) during TEP measurements. 493 
We thus repeated the above described analyses of TMS-induced oscillations in the 494 
α- and β-bands during TOI1 and TOI2, separately for suprathreshold and subthreshold 495 
MEP trials, pooled over all pre-drug measurements of Experiment 2 (to gain sufficient 496 
trial numbers and thus statistical power). While no differences were observed in either 497 
frequency band for the early synchronization (TOI1) between suprathreshold and 498 
subthreshold MEPs (all p > 0.05), we found indeed stronger β-band desynchronization 499 
in TOI2 for trials with suprathreshold compared to subthreshold MEPs (p = 0.03), 500 
whereas a similar effect for α-band desynchronization remained non-significant (p > 501 
0.05) (Figure 5). Low trial numbers and thus reduced statistical power after trial splitting 502 
did not allow statistical post-pre cluster t-test comparisons divided by sub- and 503 
suprathreshold trials and drug condition.  504 
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 505 
Figure 5. Comparison of TMS-induced α- and β-desynchronization for trials with supra- vs. 506 
subthreshold MEPs at pre-drug baseline. TFRs suggest that late α- and β-desynchronization in TOI2 507 
was smaller for (A) trials with subthreshold MEPs than for (B) trials with suprathreshold MEPs at electrode 508 
C3 (roughly overlying the left sensorimotor cortex). Topographical representations of TMS-induced α- and 509 
β-band power show that for both (C) sub- and (D) suprathreshold MEPs, desynchronization was confined 510 
to the stimulated left (and to a lesser degree contralateral right) sensorimotor cortex. (E) Direct 511 
comparison of supra vs. subthreshold MEP trials using cluster t-statistics, revealed significantly larger 512 
β-band desynchronization associated with supra- than subthreshold MEPs over the left sensorimotor 513 
cortex, whereas α-band desynchronization showed the same tendency but did not reach significance. 514 
Data were pooled over all pre-drug measures of Experiment 2 to gain sufficient statistical power despite 515 
trial splitting.  516 
3.6 Effects of drugs on resting state EEG 517 
We finally analyzed the impact of each drug on resting state spontaneous oscillatory 518 
activity without TMS events (i.e. resting state EEG). In Experiment 1, alprazolam 519 
increased spontaneous β-band power at fronto-central sites (n=13, p = 0.02; Figure 6) 520 
but had no significant effect on α-band power (p > 0.05), whereas no significant 521 
modulations could be observed for zolpidem and placebo (p > 0.05). The lack of effect 522 
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by zolpidem could be explained by the fact that we obtained resting state EEG in the 523 
eyes open condition, and that its increasing effect on ß-band power has disappeared 524 
after 90 min (Patat et al., 1994). In Experiment 2, baclofen significantly enhanced 525 
spontaneous α-band power at lateral frontal as well as medial parietal sites (p < 0.001), 526 
and β-band power at medial frontal sites (p = 0.04); diazepam decreased α-band power 527 
at a right lateral central cluster (p = 0.02) and increased β-band power at medial frontal 528 
sites (p = 0.003; Figure 6), whereas placebo did not induce any significant changes (p > 529 
0.05). Importantly, the above described drug effects on TMS-induced oscillatory power 530 
are unlikely to be explained by ceiling effects resulting from drug-induced changes of 531 
spontaneous brain oscillations. While their topographies partially overlap (both 532 
comprising medial and lateral frontal as well as medial parietal sites), and increases in 533 
spontaneous EEG power are matched by decreases in TMS-induced synchronization or 534 
increases in desynchronization (cf. Figure 5 to Figure 4), there was no significant 535 
correlation between the drug-induced changes in spontaneous α- or β-band resting 536 
state EEG oscillatory power and the respective drug effects on TMS-induced 537 
oscillations (all p > 0.3). 538 
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 539 
Figure 6. Effects of drugs on resting state EEG (eyes open): Bar charts represent absolute EEG 540 
power (mean ± SEM) pre (black) and post (grey) drug intake. Each plot shows the grand average across 541 
all subjects and the significant channels, which are indicated by black dots in the t-statistic maps. Red 542 
represents as increase of power, whereas blue depicts a decrease. For further details, see Material and 543 
Methods. 544 
 545 
4. Discussion  546 
We disentangled for the first time the mixed activity that is usually captured by TMS-547 
related spectral perturbation measures to investigate the specific contribution of induced 548 
oscillatory power after removal of the evoked responses (Figure 2), the importance of 549 
which has recently been highlighted by  Pellicciari et al. (2017). TMS induced a specific 550 
pattern of oscillatory power in the α- and ß-bands, characterized by an early 551 
synchronization over the stimulated sensorimotor and adjacent frontal cortex and a 552 
subsequent profound desynchronization over the stimulated and contralateral 553 
sensorimotor cortex (Figure 3). Pharmacological manipulation (Figure 4) suggested 554 
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that GABAAR mediated inhibition contributes to the early α-band synchronization (30-555 
200 ms after the TMS pulse) in the stimulated sensorimotor cortex, as it was increased 556 
exclusively by GABAAR positive modulators (i.e., diazepam and zolpidem, and a trend 557 
towards increase by alprazolam). Furthermore, all drugs except zolpidem increased the 558 
late ß-band desynchronization (200-400 ms after the TMS pulse) over lateral frontal and 559 
medial parietal sites, suggesting an involvement of both GABAAergic and GABABergic 560 
processes. Finally, baclofen increased the late α-band desynchronization over the 561 
stimulated sensorimotor cortex and its contralateral homologue but also adjacent lateral 562 
frontal regions, suggesting the specific contribution of late GABABR mediated inhibition. 563 
Importantly, while late α- and β-desynchronization were partially driven by 564 
somatosensory re-afferent feedback from the evoked muscle twitch (Figure 5), the 565 
observed pharmacological modulations of TMS-induced oscillatory activity cannot be 566 
attributed to pharmacologically induced changes in corticospinal excitability (Table 1), 567 
the amount of sensorimotor re-afferent feedback from the muscle twitch (Figure 5), or 568 
changes in the resting state EEG power in the respective frequency bands (Figure 6).  569 
4.1 TMS-induced oscillations in the sensorimotor cortex 570 
We characterized the spatiotemporal profile of oscillations induced by single-pulse TMS 571 
of left M1HAND. In line with the idea of site-specific ‘natural frequencies’ (Ferrarelli et al., 572 
2012; Rosanova et al., 2009), EEG responses were dominated by specific dynamics in 573 
the α- and β-bands, the prevalent oscillations of the sensorimotor system (Neuper et al., 574 
2005). TMS-induced oscillations showed an initial synchronization over the stimulated 575 
sensorimotor and adjacent lateral frontal cortex, followed by a subsequent 576 
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desynchronization over the stimulated sensorimotor cortex as well as its contralateral 577 
homologue (Figure 3). TMS-evoked responses in the α- and β-band have previously 578 
been reported (Brignani et al., 2008; Fuggetta et al., 2005; Paus et al., 2001; Van Der 579 
Werf and Paus, 2006; Van Der Werf et al., 2006; Veniero et al., 2011), but the non-580 
phase-locked modulation of α- and β-band oscillations has not been described yet. 581 
What may be their underlying mechanisms? MEP-informed control analyses, 582 
contrasting trials with suprathreshold vs. subthreshold MEPs (with identical stimulation 583 
intensity), suggest that the late β-band desynchronization over the stimulated (and 584 
contralateral) sensorimotor cortex was partially driven by muscle twitch-related 585 
somatosensory re-afferent feedback associated with suprathreshold MEPs (Figure 5). 586 
Indeed, both movement and sensory stimulation are well known to desynchronize 587 
α- and β-band oscillations in the sensorimotor cortex (Neuper et al., 2006; Pfurtscheller, 588 
2001). However, these results do not exclude the possibility that a third factor, for 589 
example spontaneous fluctuations of corticospinal excitability, accounted for both the 590 
amount of TMS-induced cortical desynchronization and the MEP amplitude. In that 591 
case, the observed β-band desynchronization would be a direct consequence of the 592 
cortical stimulation, accompanied by corresponding variations in MEP amplitude. To 593 
eventually solve this question, one would need to block sensory afference independent 594 
of corticospinal excitability or stimulation intensity, e.g., by transient ischemic forearm 595 
deafferentation (Ziemann et al., 1998).  596 
Moreover, the early synchronization of the stimulated sensorimotor cortex does 597 
not seem to be dependent on the TMS-evoked muscle twitch, as it did not differ 598 
between sub- and suprathreshold MEPs (Figure 5A-B), and may thus rather reflect the 599 
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direct transcranial excitation of the oscillation-generating circuits in the motor network. 600 
Commonly, β-band synchronization is observed during the so called ‘rebound’ phase, 601 
which follows about 200-600 ms after an initial stimulus- or movement-induced 602 
desynchronization and is usually not observed for the α-band (Neuper et al., 2006). In 603 
line with our findings, this pattern is typically located in bilateral sensorimotor cortex, 604 
with the β-band rebound specifically peaking in M1 contralateral to the movement 605 
(Jurkiewicz et al., 2006; Neuper et al., 2006). However, the TMS-induced 606 
synchronization preceded the desynchronization and thus cannot be attributed to a 607 
rebound phenomenon.  608 
Previous TMS-EEG work has described a topographically wide-spread net 609 
increase in the α- and β-band oscillatory EEG power within 530 ms after the TMS pulse, 610 
scaling with stimulation intensity (Fuggetta et al., 2005). However, early and late 611 
intervals were not distinguished, and induced oscillations were not analyzed separately 612 
from evoked responses. Therefore, evoked components may have considerably 613 
influenced these findings. Our results are in line with the oscillatory pattern observed in 614 
the local field potential of the subthalamic nucleus (STN) following TMS of the ipsilateral 615 
(and even contralateral) M1, as recorded via intracranial electrodes for deep brain 616 
stimulation in patients with Parkinson’s disease (Doyle Gaynor et al., 2008). Importantly, 617 
TMS at both suprathreshold and subthreshold intensities caused an initial β-band 618 
synchronization before 200 ms and a subsequent prolonged desynchronization (200 to 619 
600 ms) of STN β-band oscillations, again suggesting that β-band desynchronization is 620 
not entirely driven by sensory feedback. But also in that study, the induced and evoked 621 
oscillations were not disentangled, and no concurrent scalp EEG was recorded, leaving 622 
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the origin of the oscillatory change unresolved. Interestingly, no effect on α-band power 623 
was observed in the STN, in line with the idea that TMS-induced α- and β-band 624 
oscillations engage separate, though partially overlapping, circuits. While it has been 625 
suggested that rolandic α- and β-band oscillations emerge from somatosensory and 626 
motor networks, respectively (Salmelin and Hari, 1994), α-band oscillations have also 627 
been recorded from layer III of the rat M1, whereas β-band oscillations dominated in 628 
layer V (Ronnqvist et al., 2013). In summary, the observed TMS-induced 629 
synchronization-desynchronization dynamic of α- and particularly β-band oscillations 630 
over sensorimotor cortices is likely to be a direct consequence of the transcranial 631 
activation of α- and β-oscillation generating cortico-cortical and cortico-subcortical 632 
circuits, while re-afferent feedback from the muscles may further enforce cortical 633 
desynchronization.  634 
4.2 Pharmacological modulation of TMS-induced oscillations  635 
Inhibitory GABAergic neurotransmission is critical for synchronization of neural activity 636 
and generation of network oscillations (Wang, 2010). For instance, both α- and β-band 637 
oscillations have been linked to inhibitory function, i.e. the suppression of perceptual 638 
input processing via ‘pulsed inhibition’ (Jensen and Mazaheri, 2010; Klimesch et al., 639 
2007; Mathewson, 2011) and the control of motor output during response inhibition 640 
(Picazio et al., 2014; Zhang et al., 2008). Further, the period of decreased motor cortical 641 
excitability following electrical median nerve stimulation (Chen et al., 1999) may be 642 
related to the stimulation-induced β-band rebound. Accordingly, GABAergic drugs also 643 
modulated TMS-induced oscillatory power synchronization at early (30-200 ms) and 644 
desynchronization at late (200-400) post-TMS intervals, for both the α- and β-bands 645 
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(Figure 4). The rather complementary effects of GABAAR and GABABR mediated 646 
inhibition suggest that TMS-induced early synchronization and late desynchronization 647 
may be dominated by different inhibitory mechanisms. Both broad and α-1 subunit 648 
specific GABAAergic drive enhanced the early α-band synchronization. In contrast, the 649 
late ß-band desynchronization was under the influence of subunit-unspecific GABAAR 650 
and GABABR activity, whilst late α-band desynchronization was exclusively driven by 651 
GABABR neurotransmission. It is important to highlight that the two benzodiazepines 652 
diazepam and alprazolam showed highly similar effect patters, but not identical with 653 
respect to their statistical significance. Two main points have to be considered that may 654 
have contributed independently to these slight differences: (i) the two drugs were 655 
administered in two separate experiments to independent subject samples, rendering 656 
direct between-study comparisons difficult; (ii) the two drugs are highly similar but not 657 
identical, and slight differences in the pharmacokinetics may have had an impact. For 658 
instance, diazepam is more likely than alprazolam to cause drowsiness, but alprazolam 659 
is reported to have more severe withdrawal effects on discontinuation. Finally, 660 
alprazolam has a shorter half-life compared to diazepam. 661 
 How does the observed GABAergic modulation of TMS-induced oscillatory power 662 
relate to the GABAergic impact on spontaneous α- and β-band oscillations at rest and 663 
during movement-related modulation? At rest, GABAAR positive modulators 664 
consistently increase β-band power (in rolandic and frontal regions), whereas they often 665 
reduce α-band power (usually reported for parieto-occipital and not specifically for 666 
rolandic cortex). These opposing effects have been demonstrated for all drugs tested in 667 
this study, namely diazepam (Jensen et al., 2005; Saletu et al., 1987), alprazolam 668 
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(Kaplan et al., 1998; Saletu et al., 1994), and zolpidem (de Haas et al., 2010). For 669 
diazepam, we could replicate the power increase and decrease for β- and α-bands, 670 
respectively, and we also observed β-band power increase for alprazolam, but contrary 671 
to our expectations, no effects for zolpidem (Figure 6). The effect of the GABABR 672 
agonist baclofen on the resting state EEG had not been investigated before in humans. 673 
We showed a strong and topographically widespread drug-induced increase in both 674 
spontaneous α- and β-band power (Figure 6), to some extent similar to an increase in 675 
β- (but not α-) band power shown in DBA/2J mice (Marrosu et al., 2006).  676 
Conversely, during and directly after movement, GABAergic inhibition appears to 677 
enhance movement related β-band desynchronization (MRBD) but reduce subsequent 678 
post-movement β-band rebound (PMBR). While bulk GABA concentration in M1HAND, as 679 
measured by magnetic resonance spectroscopy (MRS), shows a positive relationship 680 
with individual PMBR (Gaetz et al., 2011), pharmacological manipulation of its 681 
synaptically active portion revealed the opposite. Tiagabine, a GABA reuptake inhibitor 682 
and thus receptor unspecific, increased spontaneous β-band power at rest, but 683 
enhanced MRBD and reduced PMBR (Muthukumaraswamy et al., 2013), whereas 684 
diazepam also enhanced MRBD, but did not affect PMBR (Hall et al., 2011). The 685 
authors suggested that MRBD is GABAAR dependent, whereas PMBR may be 686 
GABABR dependent. Thus, TMS-induced β-band oscillations seem to be more similar 687 
to movement-related than resting β-band oscillations, as both GABAA- and GABABergic 688 
inhibition enhanced late β-band desynchronization, and GABABR mediated inhibition 689 
also enhanced late α-band desynchronization, while GABAergic effects on spontaneous 690 
and TMS-induced oscillations did not correlate. It remains unclear why the 691 
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pharmacological enhancement of GABAergic inhibition synchronizes spontaneous but 692 
desynchronizes movement-related and TMS-induced β- (and α-) oscillations. However, 693 
our results suggest that GABAergic inhibition plays a different role in the resting and 694 
activated motor cortex. 695 
Importantly, the observed GABAergic effects on TMS-induced oscillations cannot 696 
be explained merely by TMS-evoked muscle twitches or the associated re-afferent 697 
somatosensory feedback. Firstly, drug-induced changes in TMS-induced oscillations 698 
mainly occurred over medial and lateral frontal as well as medial parietal sites, for which 699 
no somatosensory feedback-related activation was observed (Figure 4 vs. Figure 5). 700 
Secondly, diazepam and baclofen did alter TMS-induced α- and β-band oscillatory 701 
power in Experiment 2, although TMS-evoked muscle responses, and thus 702 
somatosensory afferent feedback, were unchanged, because stimulation intensity was 703 
kept constant at 100% RMT (Table 1).  704 
The question of whether or not to re-adjust stimulation intensity after a 705 
pharmacological intervention based on a certain excitability estimate (here the RMT) is 706 
difficult to answer, and there are advantages and disadvantages of both options. In fact, 707 
this dilemma holds true for any kind of intervention that modulates the excitability of 708 
certain neuron populations in the target region while using a network response (such as 709 
TMS-evoked or -induced EEG responses) as a readout. In the case of the motor cortex, 710 
readjustment of stimulation intensity to compensate for drug-induced RMT changes 711 
ensures comparable excitation of the corticospinal system and thus keeps TMS-evoked 712 
muscle responses and related sensory feedback constant. However, there are two 713 
important unknowns. Firstly, it is unclear the excitability change of which specific neuron 714 
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population gave rise to the RMT change in the first place (corticospinal motor neurons in 715 
layer IV, connected pyramidal neurons in layer II-III, interneurons, or even spinal motor 716 
neurons). And secondly, it is unknown which specific neuron populations (and even 717 
which brain regions) give rise to the TMS-evoked/-induced EEG response. Thus, if RMT 718 
reflects the excitability of cortical motor neurons, adjustment will ensure that those 719 
neurons will be effectively excited to the same degree before and after drug intake, and 720 
a changed EEG response is attributable to changed excitability of other connected 721 
regions or changed functional connectivity within the same network. Conversely, no 722 
adjustment would result in different excitation and consequently different output levels of 723 
the cortical motor neurons, ranging from no output at all (if stimulation became 724 
subthreshold) to a strong enhancement of the output to connected regions, limiting the 725 
interpretability of changed network responses. However, different stimulation intensities 726 
may also affect different neuron populations, and for other co-stimulated neuron 727 
populations, unaffected by the RMT change but involved in the network response, 728 
adjustment would result in different levels of effective excitation and thus different EEG 729 
responses (Casarotto et al., 2010). Thus, re-adjustment to RMT can be both a necessity 730 
and a potential confound when investigating changes in TMS-evoked/induced 731 
oscillatory activity after drug intake (or any other intervention). While on the expense of 732 
consistency and direct comparability between the two experiments, we were also 733 
fortunate having employed both approaches in Experiment 1 and 2, respectively, using 734 
drugs with highly comparable GABAergic effects (i.e., alprazolam and diazepam) and 735 
finding largely comparable effects for both (Figures 4A, D). Future studies, should thus 736 
evaluate post-drug (or generally post-interventional) measures with both adjusted and 737 
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unadjusted intensities to overcome these limitations. For target sites outside M1 (lacking 738 
an index such as RMT, maybe requiring electric field estimates), it is an even larger 739 
challenge to disentangle excitability changes of the transcranially stimulated neurons 740 
from that of transsynaptically stimulated ones within the connected network.  741 
4.3 Conclusion 742 
We aimed at disentangling TMS-induced (non-phase-locked) oscillatory activity 743 
following M1HAND stimulation from TMS-evoked (phase-locked) responses. Results 744 
revealed a specific and dynamic TMS-induced synchronization-desynchronization 745 
pattern in the α- and ß-bands, mainly over the stimulated and contralateral sensorimotor 746 
cortices that is complementary to TMS-evoked EEG potentials and resting-state EEG. 747 
The early α-synchronization was increased by the GABAAergic drugs and decreased by 748 
the GABABergic drug, the late α-desynchronization was increased by the GABABergic 749 
drug, and the late ß- desynchronization was increased by GABAAergic and 750 
GABABergic drugs. These findings are relevant for future investigations of GABA-751 
related alterations in functional brain connectivity, e.g., in brain network disorders such 752 
as schizophrenia or epilepsy, as functional connectivity generally employs frequency 753 
information as a code. 754 
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